Results 151 to 160 of about 2,022,996 (246)
Advanced Science, Volume 13, Issue 61, 3 November 2026.A PROTAC‐functionalized protein/DNA‐integrated nanoantigen platform is developed to enhance dendritic cell vaccine potency. By combining a VHL‐recruiting peptide‐modified antigen with a sustained expression plasmid within CaCO3 nanoparticles, this system amplifies cross‐presentation, promotes DC maturation, and elicits robust Th1 and CTL responses ...
Peng Liu +4 more
wiley +1 more source
Discover OncologyObjective The main objective of this study is to investigate the dysregulated expression, clinical relevance, and underlying mechanisms of COG8 in lung adenocarcinoma (LUAD) and other human malignancies.
Fei-Xiang Tan +6 more
doaj +1 more source
Neoadjuvant Therapy for Non‐Small Cell Lung Cancer: Recent Advances and Future Directions
Cancer Medicine, Volume 15, Issue 11, November 2026.ABSTRACT Neoadjuvant therapy has become an integral component of the multidisciplinary management of resectable non–small cell lung cancer (NSCLC). The introduction of immune checkpoint inhibitors (ICIs) has transformed the perioperative treatment landscape by improving pathological response rates, reducing the risk of recurrence, and offering the ...
Hao An +15 more
wiley +1 more source
Clinical and Translational Medicine, Volume 16, Issue 11, November 2026.This Review proposes a microbiome–premetastatic brain niche axis connecting gut, lung, and intratumoral microbes with metabolites, blood–brain barrier remodeling, neuroimmune priming, and brain metastasis in NSCLC. It integrates current evidence while distinguishing established mechanisms from associations and hypotheses requiring prospective and ...
Long Liang +8 more
wiley +1 more source
Discrepancy of tumor neoantigen burden between primary lesions and matched metastases in lung cancer
Annals of Oncology, 2018 T. Jiang, C. Zhou
openaire +1 more source
Head &Neck, Volume 48, Issue 11, Page 3103-3112, November 2026.ABSTRACT Background The benefit of consolidation programmed cell death protein 1 (PD‐1) blockade after chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (NPC) remains unclear. Methods Patients with stages II–IVB NPC were randomized (2:1) to pembrolizumab 200 mg or placebo every 3 weeks for up to 17 cycles after chemoradiotherapy ...
Sang Hoon Chun +11 more
wiley +1 more source
P1.07-026 Predicting Tumor Mutational Burden (TMB) and Tumor Neoantigen Burden (TNB) of East Asian ANSCLC Patients by a Targeted Genomic Profiling [PDF]
Journal of Thoracic Oncology, 2017 openaire +1 more source
Low tumor burden follicular lymphoma: The state of the art
HemaSphere, Volume 10, Issue 11, November 2026.Abstract Follicular lymphoma (FL) is the commonest indolent non‐Hodgkin lymphoma. Most patients present with advanced‐stage and are stratified by the Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria into high or low tumor burden (LTB). Randomized trials in LTB FL demonstrated no overall survival advantage with immediate treatment compared to ...
Greg Hapgood +3 more
wiley +1 more source
<p>HLA loss of heterogeneity (HLA LOH) and tumor neoantigen burden in relationship to clinical outcome variables in dMMR CRC.</p>
Md Mohiuddin +8 more
core +1 more source
IJU Case Reports, Volume 9, Issue 6, November 2026.ABSTRACT Introduction Urachal carcinoma is a rare and aggressive malignancy with no established systemic therapy after platinum failure. Evidence for immune checkpoint inhibitors (ICIs) remains limited, particularly in tumors without established favorable biomarkers such as microsatellite instability‐high status or high tumor mutational burden.
Fumihiro Ito +4 more
wiley +1 more source